At a recent industry event, Pharmaceutical Technology met with Jerome Detreille and Steve Tooker from PCI Pharma to discuss the changing CDMO landscape and how PCI Pharma Services through global integrated drug manufacturing and packaging solutions, will meet current and future client needs.
Key highlights of the interview include:
- Overview of challenges biopharma companies face, from their struggles to find readily available capacity at CDMOs, to the search in identifying an experienced outsourcing partner to support their novel sterile/high potent drug product throughout its development lifecycle.
- Discussion on industry challenges faced by CDMOs, including the extended lead times for materials and equipment and the importance of supply chain planning and foresight for managing project timelines to ensure the timely delivery of life-changing therapies to patients.
- The benefits of working with a single supplier throughout the product’s lifecycle to de-risk the drug product supply chain and provide cost and time-efficient integrated solutions.
- Updates on the latest developments and expansion plans across the global PCI network of high potent and sterile manufacturing together with the addition of new packaging capacities and capabilities for vials, prefilled syringes and autoinjectors.
We are committed to supporting clients at every stage of the manufacturing cycle, delivering best-in-class services efficiently and effectively.
Find out more about our fully integrated CDMO Services.